
Opinion|Videos|June 27, 2024
Biomarker Testing and Guideline-Recommended Care in mNSCLC
Mark Socinski, MD, introduces a panel of medical experts as they kick off a discussion surrounding biomarker testing and guideline recommendations in the metastatic non-small cell lung cancer treatment landscape.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- What are the current NCCN guideline recommendations regarding molecular/genetic testing (NGS, etc.) for newly diagnosed mNSCLC patients?
- Do the NCCN guideline recommendations for molecular/genetic testing and biomarker evaluation differ between squamous and non-squamous non-small cell lung cancer? If so, how, and why?
- What is the rationale and clinical utility of comprehensive biomarker testing in this setting?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
5 Ways ACOs Can Improve Care, Achieve Meaningful Savings
2
Long-Term Remission in Ph-Negative B-ALL With Sequential CAR T, ASCT
3
How Artificial Intelligence Is Transforming Leukemia Detection and Diagnosis
4
Mirvetuximab Soravtansine Demonstrates Promising Efficacy, Safety in Platinum-Resistant Recurrent Ovarian Cancer
5












































